348 related articles for article (PubMed ID: 35222418)
21. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.
Mueller MM; Fusenig NE
Differentiation; 2002 Dec; 70(9-10):486-97. PubMed ID: 12492491
[TBL] [Abstract][Full Text] [Related]
22. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion.
Rømer J; Pyke C; Lund LR; Eriksen J; Kristensen P; Rønne E; Høyer-Hansen G; Danø K; Brünner N
Int J Cancer; 1994 May; 57(4):553-60. PubMed ID: 8181859
[TBL] [Abstract][Full Text] [Related]
23. Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Csiszar A; Kutay B; Wirth S; Schmidt U; Macho-Maschler S; Schreiber M; Alacakaptan M; Vogel GF; Aumayr K; Huber LA; Beug H
Breast Cancer Res; 2014 Sep; 16(5):433. PubMed ID: 25212966
[TBL] [Abstract][Full Text] [Related]
24. The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.
O'Connell C; VandenHeuvel S; Kamat A; Raghavan S; Godin B
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077371
[TBL] [Abstract][Full Text] [Related]
25. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions.
Ohtani H
Pathol Int; 1998 Jan; 48(1):1-9. PubMed ID: 9589457
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
[TBL] [Abstract][Full Text] [Related]
27. Selective expression and function of granzyme D in lymphohematopoietic stromal cells.
Yokoi A; Kina T; Minato N
Biochem Biophys Res Commun; 1999 Nov; 264(3):768-73. PubMed ID: 10544006
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
29. Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L.
Goretzki L; Schmitt M; Mann K; Calvete J; Chucholowski N; Kramer M; Günzler WA; Jänicke F; Graeff H
FEBS Lett; 1992 Feb; 297(1-2):112-8. PubMed ID: 1551416
[TBL] [Abstract][Full Text] [Related]
30. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
[TBL] [Abstract][Full Text] [Related]
31. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells.
Festuccia C; Angelucci A; Gravina GL; Villanova I; Teti A; Albini A; Bologna M
Int J Cancer; 2000 Feb; 85(3):407-15. PubMed ID: 10652434
[TBL] [Abstract][Full Text] [Related]
32. Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR).
Beaufort N; Debela M; Creutzburg S; Kellermann J; Bode W; Schmitt M; Pidard D; Magdolen V
Biol Chem; 2006 Feb; 387(2):217-22. PubMed ID: 16497155
[TBL] [Abstract][Full Text] [Related]
33. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer.
Santibanez JF
Protein Pept Lett; 2017; 24(10):936-946. PubMed ID: 28820062
[TBL] [Abstract][Full Text] [Related]
34. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
[TBL] [Abstract][Full Text] [Related]
35. Activation of serpins and their cognate proteases in muscle after crush injury.
Festoff BW; Reddy RB; VanBecelaere M; Smirnova I; Chao J
J Cell Physiol; 1994 Apr; 159(1):11-8. PubMed ID: 8138578
[TBL] [Abstract][Full Text] [Related]
36. Expression pattern and functional studies of matrix degrading proteases and their inhibitors in the mouse corpus luteum.
Liu K; Wahlberg P; Hägglund AC; Ny T
Mol Cell Endocrinol; 2003 Jul; 205(1-2):131-40. PubMed ID: 12890575
[TBL] [Abstract][Full Text] [Related]
37. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
38. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
39. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
Weidle UH; Tiefenthaler G; Georges G
Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
[TBL] [Abstract][Full Text] [Related]
40. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
